BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress C ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive has a global presence with bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - The company employs technology to enhance workflows and has a forward-looking approach to technology adoption [4] - Proactive utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Tiziana Life Sciences has been invited to the J.P. Morgan Asset Management Life Science Innovation Forum 2025, highlighting its position in the biotechnology sector [1][2][3] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies [5] - The company's lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development [4][5] Product Development - Foralumab has shown promise in stimulating T regulatory cells when administered intranasally, with positive outcomes observed in patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) [3][4] - In an open-label intermediate sized Expanded Access Program, all 14 patients treated exhibited either improvement or stability of disease within 6 months [3] - Foralumab is also undergoing a Phase 2a randomized, double-blind, placebo-controlled trial for na-SPMS [3] Industry Context - The Life Science Innovation Forum aims to accelerate the transition of life science research into market-ready solutions and strengthen the biotechnology value chain [2] - The event is aligned with Saudi Arabia's National Biotechnology Strategy, promoting a thriving ecosystem for life sciences [2]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Insights - Proactive is a financial news and online broadcast organization that provides fast, accessible, and actionable business and finance news to a global investment audience [2][3] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's editorial and broadcast operations are managed by a seasoned team, ensuring quality control and content production across multiple global locations [1][2] Company Operations - Proactive operates with a team of experienced news journalists across key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - The organization produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - Proactive employs both human content creators and technology to enhance workflows, ensuring a blend of expertise and innovation in content production [4][5] Content Focus - The news team at Proactive delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - The company emphasizes the importance of human editing and authorship in its content production, adhering to best practices for content quality and search engine optimization [5]

Core Viewpoint - Tiziana Life Sciences is advancing its second asset, TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody, amidst increased industry activity in the IL-6 pathway, highlighted by Novartis' acquisition of Tourmaline Bio for approximately $1.4 billion [1][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, particularly intranasal administration [9][10]. Product Development - TZLS-501 targets both membrane-bound and soluble forms of IL-6R, potentially offering therapeutic advantages in managing diseases characterized by excessive IL-6 signaling, such as rheumatoid arthritis, acute respiratory distress syndrome, and various cancers [2][4]. - The company plans to pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance its lead program, intranasal foralumab [1][3]. Market Context - The recent acquisition by Novartis underscores the growing importance of IL-6 therapeutics, positioning Tiziana to capitalize on this trend with the development of TZLS-501 [3][5]. - The dual mechanism of action of TZLS-501, which inhibits IL-6R signaling and reduces circulating IL-6 cytokines, is seen as a significant advancement in treating acute and chronic inflammatory conditions [2][6]. Clinical Programs - Foralumab, Tiziana's lead candidate, is currently being studied in clinical trials for its efficacy in treating non-active secondary progressive multiple sclerosis, with positive outcomes reported in initial patient dosing [7][8].

Core Insights - Proactive is a financial news and online broadcast organization that provides fast, accessible, and actionable business and finance news to a global investment audience [2][3] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's editorial and broadcast operations are managed by a seasoned team, ensuring quality control and content production across multiple global locations [1][2] Company Operations - Proactive operates with a team of experienced news journalists across key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - The organization produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - Proactive employs both human content creators and technology, including automation and generative AI, to enhance workflows while ensuring all content is edited and authored by humans [4][5] Market Focus - The company delivers news and insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3]

Core Viewpoint - Tiziana Life Sciences is presenting a scientific poster on its Phase 2a clinical trial of intranasal foralumab for treating non-active secondary progressive multiple sclerosis at the ECTRIMS Congress, highlighting its innovative approach in immunomodulation therapies [1][2][4]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using novel drug delivery technologies, particularly intranasal delivery for immunotherapy [6][8]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in preliminary studies [5][8]. Clinical Trial Details - The poster presentation titled "Study Design of a Phase 2a Double-Blind Placebo-Controlled Trial of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis" outlines the trial's design and objectives [2][7]. - The Phase 2a trial aims to evaluate the efficacy and safety of nasal foralumab in patients with non-active secondary progressive multiple sclerosis, a group with limited treatment options [4][5]. Event Information - The ECTRIMS Congress, where the poster will be presented, is the largest annual international conference dedicated to multiple sclerosis research, taking place from September 24-26, 2025, in Barcelona, Spain [1][4][7].

Core Insights - Tiziana Life Sciences Ltd is highlighted as one of the best biotech penny stocks to invest in currently [1] Company Overview - Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotech company focused on next-generation immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer's, and multiple system atrophy [2] Management Activity - In September 2025, significant insider activity was noted, with CEO Ivor Elrifi purchasing 193,848 shares at $1.65 each, and Executive Chairman Gabriele Cerrone acquiring 25,000 shares, increasing his stake to 36.28%, indicating strong management confidence in the company's pipeline and long-term prospects [3] Recent Developments - Tiziana Life Sciences Ltd secured a U.S. Department of Defense grant on September 15, 2025, to advance the development of intranasal foralumab for spinal cord injury, expanding its focus beyond central nervous system disorders [4] - The company achieved a milestone by dosing the first patient in a Phase 2a trial for multiple system atrophy, following FDA approval of a Phase 2 IND application in August 2025 [4]

Group 1 - Berkshire Hathaway has completely divested its shares in BYD, marking the end of a 14-year investment period [10] - The investment was valued at zero as of March 31, 2023, according to Berkshire's financial documents [10] - Over the investment period, Berkshire Hathaway has reduced its holdings in BYD at least 16 times, realizing a profit of at least 8.071 billion HKD [10] Group 2 - The Chinese government is actively working on establishing national standards for pre-prepared dishes to enhance consumer rights [4][6] - The initiative involves multiple departments, including the Ministry of Industry and Information Technology and the National Health Commission [4] Group 3 - A blue alert for Typhoon "Haikui" has been issued, with expectations of severe weather impacting the South China Sea and parts of Guangdong [5] - The typhoon is predicted to approach the northeastern coast of Hainan Island, with maximum wind speeds exceeding 62 m/s [5] Group 4 - A suspected food poisoning incident in Guizhou has led to 136 individuals being hospitalized, with symptoms linked to salmonella contamination [5] - The local authorities are investigating the incident and have taken measures to seal off the affected food products [5] Group 5 - Huawei has launched the "Tian Gong Plan," committing 1 billion RMB to support the development of the HarmonyOS AI ecosystem [8] - The number of devices running HarmonyOS 5 has surpassed 17 million, indicating significant growth in the ecosystem [8]